AzTrials
AzTrials

Bipolar DepressionNCT05939115

Intensive Accelerated Theta Burst Stimulation in Treatment of Patients With Bipolar Depression and Suicidality

A study testing Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark) in people with Bipolar Depression, run by Zagazig University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The objective of this study is to compare the efficacy of left unilateral versus bilateral accelerated Theta Burst Stimulation (TBS) in suicidal reduction and in reduction of severity of depressive symptoms in patients with bipolar depression. Read more about this study

Who is it for?
Ages 19 years and older
Conditions the study is for
Bipolar Depression
What is being tested?
Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
58 participants
Where
1 siteEgypt
Study dates
1 Jun 2023to Jun 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of Major depressive episode as a part of bipolar (I or II) disorder and confirmed by Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-I)
  • Meet the threshold on the total MADRS score of >/=35 at baseline visit (severe)
  • Meet the threshold on the total BDI-II score of >/=30 at baseline visit (severe)
  • Ongoing suicidal ideation and/or behavior (confirmed with Columbia Scale for the Rating of Suicide Severity (C-SSRS) , score >/=3 (moderate to high risk)
  • Age 19 years or older (Adults, Older Adults)
  • Right handedness
Show all 10Show fewer
  • Both genders
  • Able to provide informed consent to participate in the study
  • Participants were required to have been taking a stable pharmacological regimen for 2 weeks before screening that had to include a mood stabilizer (lithium >0.6 mEq/L or valproate >350 mM/L), an atypical antipsychotic, or a combination of a mood stabilizer and an atypical antipsychotic. For participants with BD type II, lamotrigine monotherapy was acceptable if the dose was greater than 100 mg daily
  • Pass the TMS adult safety screening (TASS) questionnaire

Who cannot join

  • No current substance abuse disorder for the past 3 months (previous substance abuse not exclusionary)
  • Any psychotic disorder or current active psychotic symptoms
  • No dementia or other major neurological disorders
  • No major medical illness, for example metastatic cancer, end stage renal disease
  • Not able to verify contact information. Participants must be able to follow through with the study \& must have verified contact information and at least one verified contact
  • Pregnancy. While there are no known risks to a fetus this is a new use of TMS, which has not been tested, thus pregnancy is exclusionary
Show all 13Show fewer
  • Any history of any clinically significant neurological disorder, including organic brain disease, epilepsy, stroke, brain lesions, previous neurosurgery, or personal history of head trauma that resulted in loss of consciousness for > 5 minutes and retrograde amnesia for > 30 minutes
  • Conductive, ferromagnetic or other magnetic sensitive metals that are implanted or are non-removable within 30 cm treatment coil (around the head)
  • Score on Young Mania Rating Scale (YMRS) greater than 12 (patients with mixed features have been shown not to respond well to TMS treatment)
  • Rapid cycling Bipolar illness (patients with > 4 mood episodes within the past year will be excluded, as they have a higher risk of switch to mania)
  • Non response to ECT in current episode.
  • Current severe insomnia (must sleep a minimum of 5 hours the night before stimulation)
  • Are currently (or in the last 4 weeks) taking lorazepam greater than 2 mg daily (or equivalent) due to the potential to limit rTMS efficacy

Trial locations and contacts

1 site in 1 country.

Medhat M Bassiony, Professor contact

+2001005334253

mbassiony@hotmail.com

Alaa E Zayed, Ass.Lecturer contact

+2001116277409

alaaelsayedzayed@gmail.com

Egypt1 site, 1 recruiting
  • Zagazig University

    Zagazig, 7120730

    Medhat M Bassiony, Professor, +2001005334253, mbassiony@hotmail.com

    Alaa E Zayed, Ass.Lecturer, +2001116277409, alaaelsayedzayed@gmail.com

    Recruiting

Other trials in Egypt

About this study

Official title: Efficacy of Unilateral Versus Bilateral Accelerated Theta Burst Stimulation in Treatment of Patients With Bipolar Depression and Suicidality

The objective of this study is to compare the efficacy of left unilateral versus bilateral accelerated Theta Burst Stimulation (TBS) in suicidal reduction and in reduction of severity of depressive symptoms in patients with bipolar depression.

Read the detailed description

Introduction:

Repetitive transcranial magnetic stimulation (rTMS) therapy is a noninvasive neurostimulation treatment that has been adopted as a first-line treatment for pharmacotherapy-resistant major depressive disorder (MDD) (Milev et al., 2016). rTMS induces electrical activity in the cortex using magnetic fields generated outside of the head. However, the evidence for antidepressant efficacy of rTMS in the treatment of bipolar depression is limited and derived primarily from small trials (Tavares et al., 2017, Dolberg et al., 2002, Nahas et al., 2003, Beyne et al., 2014, Tamas et al., 2007) and subsets of trials in major depression that included individuals with bipolar disorder (McGirr et al., 2016, Nguyen et al., 2021 ).

The proposed study will examine sequential bilateral versus Unilateral accelerated theta burst stimulation (aTBS) in treatment of patients with bipolar depression and suicidality.

Hypothesis:

We assume that bilateral accelerated TBS is superior than left unilateral accelerated TBS in treatment of suicidality while bilateral accelerated TBS is as effective as left unilateral accelerated TBS in treatment of depressive symptoms in bipolar patients.

Aim:

This study aims to reduce morbidity and mortality of bipolar depressive patients and to improve overall functioning.

Objectives:

  1. To compare efficacy of left unilateral versus bilateral accelerated TBS in suicidal reduction in patients with bipolar depression.
  2. To compare efficacy of left unilateral versus bilateral accelerated TBS in reduction of severity of depressive symptoms in bipolar disorder as well as response and remission rates.
  3. To investigate association between the reduction of suicidality and the reduction of depressive symptoms

Subjects and methods

  1. Technical design: Site of the study: psychiatric department TMS Unit at Zagazig University Hospital Sample size: Assuming that Percent of improvment of depression scale in bipolar patients ( response rate) in unilateral TMS was 47% and bilateral TMS was 80% (Kazemi et al.,2016) so at power of study 80% and confidence interval 95%, the sample size was calculated to be 58 cases ( 29 in each group) ( Open Epi )
  • The samples will be allocated randomly into two groups (1:1) :
  • First group: will be treated by left unilateral accelerated TBS
  • Second group: will be treated by bilateral accelerated TBS
  1. Operational design
  • Study design:
  • Open label randomized clinical trial with two parallel treatment arms
  • Methods:
  • Patients will be allocated randomly into two groups (1:1).
  • The randomization scheme was generated by using the Web site Randomization.com ⟨http://www.randomization.com⟩.
  • Group 1 will receive (left unilateral aTBS); group 2 will receive ( bilateral aTBS)
  • Device: MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)
  • Details of treatment sessions:
  • Group 1 (left unilateral aTBS): "Active comparator"
  • They will receive accelerated iTBS. Stimulation with F-8 coil was administered to the left dorsolateral prefrontal cortex (DL-PFC) determined using Beam method. Stimulation was at 90% MT intermittent theta burst (iTBS) for 1800 pulses with an intertreatment interval of fifty minutes. Patients received ten sessions every day for five consecutive days for a total of fifty sessions (90,000 pulses).
  • Group 2 ( bilateral aTBS) : "Active comparator"
  • Bilateral accelerated theta burst stimulation (aTBS). Ten sessions are administered daily for five consecutive days for a total of fifty sessions .During each session continuous theta burst stimulation (cTBS) in which (1800 pulses) are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDLPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDLPFC) with using beam method for target localization .
  • The theta burst stimulation (TBS) parameters were adopted from prior work, with 3-pulse 50 Hz bursts given every 200 ms (at 5 Hz) with an intensity of 90% of resting motor threthold (RMT)
  • Motor threshold: Using single pulse TMS, the scalp position of lowest motor threshold over primary motor cortex to produce visual contraction of the first dorsal (thumb) interosseous or abductor pollicis brevis muscle . Resting motor threshold (MT) was defined using the Adaptive Pest online algorithm.

Participants :

All the participants who will be enrolled in the study will be subjected to the following:

  1. A semi-structured interview will be employed to obtain socio-demographic and clinical data.
  2. Psychometric tools:

The scales will be done at baseline and at the end of each day of five treatment days .

  1. Montgomery-Asberg depression rating scale (MADRS)
  2. The Beck Depression Inventory
  3. Columbia Suicide Severity Rating Scale (C-SSRS)
  4. Young Mania Rating Scale (YMRS)

Administrative design

  • Approval was obtained from the Institutional Review Board (IRB) and the Department of Psychiatry, Zagazig University, Egypt.
  • A written consent will be signed by the study participants.
Being tested
Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)
Medical subject headings
Bipolar Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)Device

    TMS Therapy System with Theta Burst Stimulation

Study groups in NCT05939115
Study groupRoleWhat they receive
Left unilateral aTBSActive comparatorParticipants who are randomly assigned to this group will receive iTBS (intermittent theta burst stimulation) to the left dorsolateral prefrontal cortex (LDLPFC) determined using Beam method for 1800 pulses with an intertreatment interval of fifty minutes. Stimulation was at 90% of resting motor threshold. Patients received ten sessions every day for five consecutive days for a total of fifty sessions (90,000 pulses).
Receives: Device: Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)
Sequential bilateral aTBSActive comparatorParticipants who are randomly assigned to this group will receive ten sessions daily for five consecutive days for a total of fifty sessions. During each session continuous theta burst stimulation (cTBS) in which (1800 pulses) are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDLPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDLPFC) with using beam method for target localization. Stimulation was at 90% of resting motor threshold.
Receives: Device: Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in suicidal ideation and behaviors as measured by Columbia Suicide Severity Rating Scale (C-SSRS)

    The SI severity scale is composed of five yes=no questions of increasingly severe suicidal thoughts: a wish to be dead (1), non-specific suicidal thoughts (2), suicidal thoughts with a method (3), suicidal intent without specific plan (4), and suicidal intent with specific plan (5).

    This scale was scored from 0 to 5 according to the most severe suicidal ideation endorsed. Higher scores mean worse outcome.

    Suicidal behaviors were assessed dichotomously (yes=no) and include actual suicide attempts, interrupted suicide attempts, aborted suicide attempts, other preparatory acts (e.g., collecting pills, writing suicide note), and non-suicidal self-injury (NSSI).

    Measured: Assessed at baseline (day 0) , post-inpatient treatment completion (day 5) , 1 month ,3 month and 6 month.

Secondary outcomes (1)
  1. Change from baseline Montgomery-Åsberg Depression Rating Scale (MADRS) Score

    The Montgomery-Åsberg Depression Rating Scale (MADRS), is a ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.

    Remission is defined as MADRS ≤10. Response is defined as a reduction of >/=50% of MADRS baseline score.

    Measured: Assessed at baseline (day 0) , post-inpatient treatment completion (day 5) , 1 month ,3 month and 6 month.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jul 2023
  2. Study start1 Jun 2023
  3. Primary completionMay 2025 (estimated)
  4. Study completionJun 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
58 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05939115
Sponsor's protocol ID
9697
Status last verified
Jun 2023
First submitted
24 Jun 2023
Last updated
11 Jul 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark) in people with Bipolar Depression, run by Zagazig University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Medhat M Bassiony, Professor (+2001005334253, mbassiony@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in suicidal ideation and behaviors as measured by Columbia Suicide Severity Rating Scale (C-SSRS) (time frame: Assessed at baseline (day 0) , post-inpatient treatment completion (day 5) , 1 month ,3 month and 6 month.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in